BOULDER — Edgewise Therapeutics Inc. (Nasdaq: EWTX) has issued a prospectus for a shelf registration that could raise up to $400 million.
The company, which was founded in 2017, is focused on developing drugs to treat muscular disorders. Its leading candidate, called EDG-5506, is designed to treat Duchenne muscular dystrophy and Becker muscular dystrophy, two rare forms of the disorder that target the hips, thighs, upper arms and shoulders.
Edgewise also has two other potential medicines in the pipeline. EDG-5440 is designed to treat neuromuscular disorders and EDG-002 is designed to treat inherited hypertrophic cardiomyopathy.